TNF and early-onset autosomal dominant Alzheimer disease: Promising results from epidemiological studies and small-scale clinical trials also suggest that exposure to anti-TNF agents reduces incidence or severity of Alzheimer’s disease in humans, though there is scope for future large-scale randomized clinical trials to confirm these, at times, contradictory results (Ekert et al., 2018).